#South Korea #Samsung Biologics #Incheon #CDMO #Samsung Bioepis

Samsung Biologics Enhances Focus with Successful Spin-Off

In a significant move to tighten its strategic focus, Samsung Biologics, listed on Korea's KRX under the ticker 207940.KS, has finalized the spin-off of Samsung Bioepis. This decision reflects the company’s aim to operate strictly as a pure-play Contract Development and Manufacturing Organization (CDMO). The initiative comes as a part of its broader vision to enhance its specialization in the biotechnology sector.

The spin-off was announced on November 1, following the necessary approvals from the company’s Board of Directors and a shareholders' meeting where an overwhelming 99.9% voted in favor of the separation. This decisive support demonstrates robust confidence from investors in Samsung Biologics' strategic direction. The company had earlier proposed the plan in May, and within a span of just five months, it has successfully organized all pertinent steps, including regulatory approvals and setting up Samsung Epis Holdings, the new entity formed from the spin-off.

Samsung Biologics has temporarily halted trading of its shares until November 21, after which the company will resume trading along with the newly established Samsung Epis Holdings. This strategic separation is expected to unlock new growth potential for Samsung Biologics, particularly in expanding its production capacities and diversifying its service offerings. As part of its long-term vision, the company aims to enhance its global presence and extend its services to more clients in the biopharma sector.

The roadmap laid out by Samsung Biologics includes ambitious plans for growth. By 2032, the organization expects to complete the construction of its second Bio Campus, which will elevate its biomanufacturing capacity to a staggering total of 1,324,000 liters. To stay ahead in the evolving biotech landscape, the company intends to broaden its service portfolio, with specific attention on next-generation modalities including antibody-drug conjugates (ADCs) and organoids.

Currently, Samsung Biologics services 17 of the top 20 pharmaceutical companies globally. The company is set to widen its clientele further, looking to encompass the top 40 global biopharma entities and expand interactions in key markets like Japan and the broader Asia-Pacific region.

John Rim, President and CEO of Samsung Biologics, expressed optimism regarding the spin-off, stating, “This strategic separation positions us firmly as a pure-play CDMO and establishes a solid foundation for ongoing global growth.” He reassured stakeholders of the company’s commitment to operational excellence and delivering long-term value for clients and patients alike.

About Samsung Biologics

Samsung Biologics is recognized as a preeminent CDMO focusing on providing comprehensive services that span the spectrum from late-stage discovery to commercial manufacturing. With five plants and a combined biomanufacturing capacity of 784,000 liters, the company employs advanced technologies to produce a diverse range of modalities, including multispecific antibodies, fusion proteins, ADCs, and mRNA therapeutics.

Leveraging the ExellenS™ framework, Samsung Biologics enhances its manufacturing effectiveness through standardized designs and unified processes, ensuring quick and consistent production across its facilities. The company maintains a strong presence in key markets with commercial offices located in Korea, the U.S., and Japan. Its U.S. division supports clients across North America and Europe, while its Tokyo office caters to clients in the Asia-Pacific.

With continued investments in innovative capabilities, Samsung Biologics prioritizes operational excellence and quality assurance, guaranteeing the timely, reliable delivery of high-quality biomedicines. As the company advances, it remains dedicated to sustainable business practices that contribute positively to global health and societal wellbeing.

For further details, please visit Samsung Biologics.